Taisuke Nakazawa
Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor.
Journal: Cell reports. Medicine
Published: May 02, 2024
Effect of antiemetics on zolbetuximab-induced gastric injury and emesis in ferrets.
Journal: Journal of pharmacological sciences
Published: March 25, 2024
Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
Journal: Journal of pharmacological sciences
Published: December 12, 2023
Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.
Journal: Oncotarget
Published: December 20, 2022
Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.
Journal: Bioorganic & medicinal chemistry
Published: November 27, 2020
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.
Journal: Oncotarget
Published: June 20, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026